MFDS Expands Silicone Sealants Regulation in Korea with Mandatory ISO 10993-5 Testing

On May 8, 2026, the Korean Ministry of Food and Drug Safety (MFDS) issued Medical Device Raw Materials Notification No. 2026-11, introducing new regulatory requirements for silicone sealants used in medical device packaging—including IVD instrument housings and implantable device encapsulation. This update directly affects manufacturers and exporters supplying to the Korean medical device market, particularly those based in China and other export-oriented regions.

Event Overview

Effective October 1, 2026, all silicone sealants notified for use in medical device packaging in Korea must submit a validated ISO 10993-5 cytotoxicity test report. The test must demonstrate ≥95% cell viability. The requirement is stipulated in MFDS’s Medical Device Raw Materials Notification No. 2026-11, published on May 8, 2026. No transitional provisions or grandfathering clauses are indicated in the publicly available notification.

Industries Affected by This Regulatory Change

Direct Exporters (e.g., Chinese silicone material suppliers)

Exporters submitting raw material notifications to MFDS for silicone sealants will face mandatory pre-market documentation updates. Failure to include compliant ISO 10993-5 reports will result in notification rejection. As MFDS does not accept test reports from non-accredited labs, exporters must verify laboratory accreditation status before submission.

Medical Device Manufacturers (OEMs & ODMs)

OEMs and ODMs integrating silicone sealants into final devices—especially for IVD enclosures or implant-adjacent applications—must now ensure their material dossiers meet the updated MFDS requirement. This may trigger requalification of existing supply chains and impact time-to-market for new product registrations in Korea.

Contract Testing & Regulatory Support Providers

Laboratories offering biocompatibility testing services must hold CNAS accreditation specifically for ISO 10993-5 (not just general ISO 17025). Providers without this scope may not issue valid reports for MFDS submissions. Clients relying on such labs face potential delays or invalid submissions.

What Enterprises and Practitioners Should Focus On and How to Respond

Monitor official MFDS guidance and implementation clarifications

The notification references ISO 10993-5 but does not specify test conditions (e.g., extraction method, cell line, exposure duration). MFDS may issue supplementary Q&A or technical notes before October 2026. Stakeholders should track MFDS’s official website and registered notification channels for updates.

Verify laboratory accreditation scope prior to testing

CNAS accreditation must explicitly cover ISO 10993-5 cytotoxicity testing—not just ISO 10993 series in general. Exporters should request formal accreditation certificates and scope documents from labs, confirming inclusion of “cytotoxicity testing per ISO 10993-5” under CNAS registration.

Assess current material dossiers for Korean market submissions

Companies with pending or previously approved silicone sealant notifications should review whether existing ISO 10993-5 data meets the new ≥95% viability threshold and whether reports were generated under accredited conditions. Retesting may be necessary if documentation is incomplete or outdated.

Engage with Korean regulatory agents early

MFDS requires local authorized representatives for raw material notifications. Exporters should confirm their agent’s familiarity with the updated requirement and align timelines for dossier preparation, testing, and submission well ahead of the October 1, 2026 deadline.

Editorial Perspective / Industry Observation

Observably, this change reflects MFDS’s ongoing alignment with global biocompatibility expectations for materials in direct or indirect patient contact—particularly where sealing compounds interface with device surfaces that may contact tissues or bodily fluids. Analysis shows the requirement is not an isolated tightening, but part of a broader trend toward harmonizing raw material controls with ISO 10993 standards across Asia-Pacific jurisdictions. However, it remains a procedural signal rather than a fully implemented outcome: the absence of published enforcement protocols, grace periods, or lab recognition lists means practical implementation details are still emerging. From an industry perspective, this is best understood as a compliance inflection point—not yet a settled operational norm, but one requiring proactive readiness.

This regulatory update underscores how national-level raw material controls increasingly shape upstream supply chain decisions. For exporters and device manufacturers alike, it signals a shift from process-based declarations to evidence-backed biological safety verification—especially where silicone sealants serve functional roles beyond mechanical adhesion (e.g., barrier integrity in sterile or implantable contexts). Current interpretation favors treating the requirement as a near-term procedural milestone rather than a long-term strategic pivot—yet its timing suggests growing scrutiny of polymer-based medical device components across multiple markets.

Information Source: Korean Ministry of Food and Drug Safety (MFDS), Medical Device Raw Materials Notification No. 2026-11, published May 8, 2026. Pending clarification on test methodology specifications and laboratory recognition procedures remains under observation.